跳转到内容

罗索那班

维基百科,自由的百科全书
罗索那班
臨床資料
ATC碼
  • 未分配
识别信息
  • (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-piperidinyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
CAS号861151-12-4
PubChem CID
ChemSpider
UNII
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C21H21Cl3N4O
摩尔质量451.78 g·mol−1
3D模型(JSmol英语JSmol
  • O=C(NN1CCCCC1)\C4=N\N(c2ccc(Cl)cc2Cl)C(c3ccc(Cl)cc3)C4
  • InChI=1S/C21H21Cl3N4O/c22-15-6-4-14(5-7-15)20-13-18(21(29)26-27-10-2-1-3-11-27)25-28(20)19-9-8-16(23)12-17(19)24/h4-9,12,20H,1-3,10-11,13H2,(H,26,29)
  • Key:WMMMJGKFKKBRQR-UHFFFAOYSA-N

罗索那班INN:Rosonabant,开发代号:E-6776)或译作罗索纳班,是一种用作CB1受体拮抗剂/反向激动剂药物埃斯特夫正在研究将其作为治疗肥胖症食欲抑制剂[1][2]在相关的CB1拮抗剂利莫那班于2008年11月停用后不久,临床用药的开发明显停止,原因是有报道称其及其它类似药剂会引起严重的精神不良反应,例如焦虑抑郁自杀意念[3][4][5]

参见

参考资料

  1. ^ Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs. March 2009, 14 (1): 43–65. PMID 19249987. S2CID 74250986. doi:10.1517/14728210902736568. 
  2. ^ Tim C. Kirkham; S. J. Cooper. Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. 2007: 325 [12 May 2012]. ISBN 978-0-12-370633-1. 
  3. ^ Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology. December 2009, 68 (6): 861–74. PMC 2810797可免费查阅. PMID 20002080. doi:10.1111/j.1365-2125.2009.03549.x. 
  4. ^ Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current Topics in Medicinal Chemistry. 2009, 9 (6): 482–503. PMID 19689362. doi:10.2174/156802609788897844. (原始内容存档于2013-05-22). 
  5. ^ Moreira, Fabrício A.; Crippa, José Alexandre S. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria. June 2009, 31 (2): 145–153. ISSN 1516-4446. PMID 19578688. doi:10.1590/S1516-44462009000200012可免费查阅.